Searchable abstracts of presentations at key conferences in endocrinology

ea0009s28 | Symposium 7: The hypothalamic–pituitary–adrenal axis and inflammation | BES2005

Neuroendocrine and immune changes associated with autoimmune disease

Harbuz M

The long-term effects of an acute stress on subsequent HPA axis activity are well established. We have investigated the effects of different acute stressors on HPA activity, and the severity of inflammation in the rat model of adjuvant-induced arthritis (AA). A single injection of LPS administered to neonates can protect these rats from developing inflammation in response to adjuvant injection as adults. Similarly, LPS given to adults 3 weeks prior to adjuvant injection can pr...

ea0009s49 | Clinical Management Workshop 4: Endocrine sequelae of childhood cancer | BES2005

Ovarian reserve after chemotherapy

Davis M

The greatly improved survival of children and adolescents with malignancy now makes it important to assess the long-term adverse effects of cancer therapy. Loss of fertility is reported by cancer survivors to be a major concern. In women, this largely relates to gonadotoxicity of chemotherapy or local radiotherapy; uterine damage is less common and follows pelvic surgery or radiotherapy. All chemotherapeutic agents are gonadotoxic, but particularly the alkylating agents such a...

ea0008s21 | Neuroendocrine tumours-an update | SFE2004

Introduction to NET: Definition, classification and diagnosis

Caplin M

Neuroendocrine tumours are relatively rare tumours however the incidence has increased over the last 20 years from approximately 2 per 100,000 to 4 per 100,000 per year. These tumours are derived from the diffuse endocrine system and can be found anywhere in the body. They are classified according to their site of origin and whether they are functioning (hormone secreting) or non-functioning (non-hormone secreting). There are many types of neuroendocrine tumours including: med...

ea0008s31 | Endocrine aspects of breast cancer | SFE2004

Endocrine treatment of breast cancer

Dowsett M

For the last 3 decades tamoxifen has been the mainstay of the endocrine treatment of breast cancer. In early hormone receptor positive disease, 5 years of tamoxifen reduces the annual odds of death by c.25% and this has been a major contributor to the reduction in mortality from breast cancer in the UK since 1988. The generally good tolerability of tamoxifen has also led to its use in trials of chemoprevention where it has been found to reduce the early risk of presenting with...

ea0007s23 | Neural migration in neuroendocrine systems | BES2004

Recent advances in pituitary development

Dattani M

Recent advances in our knowledge of pituitary development, acquired mainly from animal models, have enhanced our understanding of the aetiology of isolated growth hormone deficiency (IGHD) and combined pituitary hormone deficiency (CPHD). A number of developmental genes known to be important for organ commitment and cell differentiation and proliferation (HESX1, LHX3, LHX4, PROP1 and PIT1) have been implicated in CPHD with or without other sy...

ea0007s25 | Hair: too little, too much | BES2004

Gene regulation and the developing hair follicle

Philpott M

The hair follicle is the most prominent cutaneous mini-organ and one of the defining features of mammalian species. Hair follicle development is driven and controlled by a series of precisely choreographed, reciprocal epithelial?mesenchymal interactions involving secreted growth factors, differentially expressed growth factor receptors and transcription factors, adhesion molecules and changes in the extracellular matrix milieu. Key amongst these signalling pathways during earl...

ea0007s38 | Insulin delivery systems | BES2004

Pancreatic islet transplantation

Press M

It is not possible even with the most intensive conventional insulin regimens to control Type 1 diabetes well enough to normalise metabolic control or totally prevent complications. For this, a closed loop is needed, whereby circulating insulin levels are regulated on a moment to moment basis according to needs. Only pancreatic transplantation currently achieves this. Over 20000 whole pancreas transplants have been done worldwide and a one year graft survival rate of over 80% ...

ea0007p78 | Endocrine tumours and neoplasia | BES2004

Proliferation of colon cancer cell line and parathyroid hormone-related peptide gene

Alokail M

Parathyroid hormone-related peptide (PTHrP)have been found to be expressed in a variety of human tumors including colon and it was originally identified as the causative agent of humoral hypercalcemia of malignancy (HHM), We used a human colonic cell line (LOVO) as a model to study the mechanism for the proliferative effects of PTHrP. The PTHrP constructs expressing PTHrP in sense or antisense orientation were constructed by cloning hPTHrP complementary DNA (cDNA) coding for a...

ea0006s1 | Society for Endocrinology Asia and Oceanic Medal Lecture | SFE2003

New insights into growth hormone action

Waters M

Growth hormone (GH) is the major regulator of postnatal growth and an important metabolic regulator. It modulates a variety of processes in many tissues, ranging from adipogenesis to neurogenesis and immune function.GH is currently thought to activate its receptor through hormone-induced dimerization, resulting in activation of the Janus kinase, JAK2. However, we find that the receptor exists as a dimer in the plasma membrane before hormone binding, base...

ea0006s1biog | Society for Endocrinology Asia and Oceanic Medal Lecture | SFE2003

Society for Endocrinology Asia and Oceanic Medal Lecture

Waters M

Mike Waters, Institute for Molecular Bioscience, University of Queensland, St Lucia, Australia AbstractProfessor Mike Waters is an NHMRC Principal Research Fellow at the Institute for Molecular Bioscience and School of Biomedical Sciences, University of Queensland. Mike has been involved in the study of GH action for over 30 years. It was his pioneering work in purifying and characterizing the GH receptor, its related ...